Table 1.

Age and tumor characteristics of study participants from HEBCS and POSH GWS, POSH validation, and SUCCESS-A

CharacteristicsHEBCS GWSPOSH GWSPOSH ValidationSUCCESS-A
Number of cases8055361,4153,596
Vital status
 Alive466 (58%)300 (56%)1,194 (84%)3,389 (94%)
 Deceased: all-cause339 (42%)236 (44%)221 (16%)207 (6%)
 Deceased: BC-specific312 (39%)235 (44%)208 (15%)NA
Follow-up mean ± SD10.6 ± 6.64.1 ± 2.05.0 ± 1.93.9 ± 1.7
Age, mean [range], y54.1 [22–87]35.8 [18–41]35.8 [18–40]53.6 [19–85]
ER
 Negative230 (29%)370 (69%)318 (22%)1,106 (31%)
 Positive513 (64%)165 (31%)1,089 (77%)2,458 (68%)
 Missing, n.62 (8%)1 (0.2%)8 (1%)32 (1%)
Grade
 1144 (18%)13 (2%)106 (7%)165 (5%)
 2312 (39%)84 (16%)549 (39%)1,698 (47%)
 3280 (35%)422 (79%)726 (51%)1,698 (47%)
 Missing, n.69 (9%)17 (3%)34 (2%)35 (1%)
T
 1390 (48%)232 (43%)692 (49%)1,464 (41%)
 2304 (38%)236 (44%)493 (35%)1,856 (52%)
 350 (6%)49 (9%)49 (3%)192 (5%)
 447 (6%)12 (2%)34 (2%)50 (1%)
 Missing, n.14 (2%)7 (1%)147 (10%)34* (1%)
N
 Negative338 (42%)248 (46%)654 (46%)1,248 (35%)
 Positive446 (55%)262 (49%)742 (52%)2,311 (64%)
 Missing, n.21 (3%)26 (5%)19 (1%)37 (1%)
M
 Negative740 (92%)481 (90%)1,398 (99%)3,487 (97%)
 Positive57 (7%)50 (9%)10 (0.7%)4 (0.1%)
 Missing, n.8 (1%)5 (1%)7 (0.3%)105 (2.9%)
Adjuvant chemotherapy treatmenta364 (45%)518 (96.6%)1,018 (72%)3,596 (100%)
 A&T14 (2%)129 (24%)187 (18%)
 Antracyclines191 (24%)376 (70%)817 (80%)3,596 (100%)
 Taxanes2 (0.2%)8 (1.5%)5 (0.5%)
 CMF153 (19%)4 (1%)9 (1%)
Adjuvant Endocrine treatmenta,b240 (29.8%)155 (29%)1,027 (72.6%)2,458 (68%)
 Anti-estrogen (Tamoxifen)234 (29%)145 (27%)966 (68%)2,458 (68%)
 Aromatase inhibitor6 (20.7%)9 (1.7%)33 (2%)223 (6%)
 LHRH agonist049 (9%)250 (17.7%)29 (1%)
 No endocrine treatment (tamoxifen/AI/LHRH agonist)272 (34%)10 (1.8%)57 (4%)0

Abbreviations: NA, not available; T, tumor size according to TNM classification; N, metastasis to lymph node; M, distant metastasis.

  • aThe total numbers may not add up, because a patient may have received several types of adjuvant chemotherapy/endocrine treatment.

  • bAmong ER-positive patients.